-
Mashup Score: 5Lower Dose of Mpox Vaccine Is Safe and Generates Six-Week Antibody Response Equivalent to Standard Regimen - 5 day(s) ago
A dose-sparing intradermal mpox vaccination regimen was safe and generated an antibody response equivalent to that induced by the standard regimen at six weeks (two weeks after the second dose), according to findings presented today at the European Society of Clinical Microbiology and Infectious Diseases Global Congress in Barcelona. The results suggest that antibody responses contributed to the effectiveness of dose-sparing mpox vaccine regimens used during the 2022 U.S. outbreak.
Source: www.niaid.nih.govCategories: General Medicine News, Infectious DiseaseTweet
-
Mashup Score: 6The HIV Field Needs Early-Stage Investigators (VIDEO) - 11 day(s) ago
The HIV research community is led by scientists with deep personal commitments to improving the lives of people with and affected by HIV. Our collective decades of work have generated HIV testing, prevention and treatment options beyond what we could have imagined in the 1980s. Those advances enable NIAID to explore new frontiers: expanding HIV prevention and treatment modalities, increasing understanding of the interplay between HIV and other infectious and non-communicable diseases, optimizing choice and convenience, and building on the ever-growing knowledge base that we need to develop a preventive vaccine and cure. The next generation of leaders will bring these concepts to fruition, and we need to welcome and support them into the complex and competitive field of HIV science.
Source: www.niaid.nih.govCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 28
Sexually transmitted infections (STIs) are caused by bacteria, viruses, or parasites. NIAID supports research across the spectrum from basic to clinical science to develop effective diagnostic, preventive and therapeutic approaches to STIs in alignment with the National STI Strategic Plan. In recognition of National STI Awareness Week, NIAID shares a snapshot of new projects and recent scientific advances in STI research.
Source: www.niaid.nih.govCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 4NIAID Funding News - 1 month(s) ago
NIAID Funding News provides funding, policy, and other information to NIAID’s extramural research community and Institute staff.
Source: www.niaid.nih.govCategories: General Medicine News, Infectious DiseaseTweet
-
Mashup Score: 10Vaginal Ring and Oral Pre-Exposure Prophylaxis Found Safe for HIV Prevention Throughout Pregnancy - 2 month(s) ago
The monthly dapivirine vaginal ring and daily oral pre-exposure prophylaxis (PrEP) with tenofovir disoproxil fumarate and emtricitabine were each found to be safe for HIV prevention among cisgender women who started using one of them in their second trimester of pregnancy, according to findings presented today at the 2024 Conference on Retroviruses and Opportunistic Infections (CROI) in Denver. Pregnant people are estimated to be three times more likely to acquire HIV through sexual intercourse than similarly aged people who are not pregnant.
Source: www.niaid.nih.govCategories: General Medicine News, Infectious DiseaseTweet
-
Mashup Score: 43Toward a Deeper Understanding of Effective Oral HIV Pre-Exposure Prophylaxis Use in Cisgender Women - 2 month(s) ago
Pivotal studies supported by NIAID demonstrated that oral pre-exposure prophylaxis (PrEP) reduces an individual’s likelihood of acquiring HIV through sex by up to 99% when taken as prescribed. Research has revealed important differences in individual and population-group preferences in oral PrEP use, particularly that cisgender women participating in studies often did not take oral PrEP as prescribed—and the intervention’s effectiveness declined when doses were taken less frequently. Jeanne Marrazzo, M.D., M.P.H. and colleagues conducted a pooled analysis of data from post-marketing demonstration projects to to characterize the relationship between oral PrEP use and its efficacy among cisgender women.
Source: www.niaid.nih.govCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 3NIAID Funding News - 2 month(s) ago
NIAID Funding News provides funding, policy, and other information to NIAID’s extramural research community and Institute staff.
Source: www.niaid.nih.govCategories: General Medicine News, Infectious DiseaseTweet
-
Mashup Score: 52Statement: Long-Acting HIV Treatment Demonstrates Efficacy in People with Challenges Taking Daily Medicine as Prescribed - 2 month(s) ago
Long-acting antiretroviral therapy (ART) with cabotegravir and rilpivirine was superior in suppressing HIV replication compared to daily oral ART in people who had been unable to maintain viral suppression through an oral daily regimen, according to interim data from a randomized trial. Upon review of these findings, an independent Data and Safety Monitoring Board (DSMB) recommended halting randomization and inviting all eligible study participants to take long-acting ART.
Source: www.niaid.nih.govCategories: General Medicine News, HIV/AIDSTweet
-
Mashup Score: 4Switching to Vegan or Ketogenic Diet Rapidly Impacts Immune System - 3 month(s) ago
Researchers at the National Institutes of Health observed rapid and distinct immune system changes in a small study of people who switched to a vegan or a ketogenic (also called keto) diet. Scientists closely monitored various biological responses of people sequentially eating vegan and keto diets for two weeks, in random order.
Source: www.niaid.nih.govCategories: General Medicine News, General HCPsTweet-
Switching to #Vegan or #Ketogenic #Diet Rapidly Impacts #ImmuneSystem | NIAID: National Institute of Allergy and Infectious Diseases https://t.co/BlqkcpH9cg Differential peripheral immune signatures elicited by vegan versus ketogenic diets in humans https://t.co/MZ5Y61ouGP… https://t.co/zf5qxXGEzw
-
-
Mashup Score: 11NIH Clinical Trial of Tuberculous Meningitis Drug Regimen Begins - 5 month(s) ago
A trial of a new drug regimen to treat tuberculous meningitis (TBM) has started enrolling adults and adolescents in several countries where tuberculosis (TB) is prevalent. The Improved Management with Antimicrobial Agents Isoniazid Rifampicin Linezolid for TBM (IMAGINE-TBM) trial will compare a six-month regimen of four drugs with the nine-month, standard-of-care regimen for TBM. The study aims to generate evidence that could improve treatment for people with TBM.
Source: www.niaid.nih.govCategories: General Medicine News, Infectious DiseaseTweet
🆕 @ECCMID A dose-sparing #mpox #vaccine regimen was safe and generated an antibody response equivalent to that induced by the standard regimen at six weeks in a #NIAID-sponsored study presented at #ESCMIDGlobal2024. https://t.co/SLFjYQ9PnE